PharmAthene presents new Sparvax anthrax vaccine data
Bradford Powell, the director of analytical sciences at PharmAthene, gave a poster presentation entitled, "Evidence Correlating Changes in Structure and Biological Activity for a Recombinant Protective Antigen (rPA) Anthrax Vaccine." Powell presented PharmAthene's achievements in developing new analytical methods to measure how changes in rPA's structural characteristics impact the stability and potency of the anthrax vaccine.
Deamidation of rPA has been identified as the most likely pathway of degradation. PharmAthene developed methods to assess the state of deamidation over time and its relationship to the potency of the vaccine. The study's results confirmed a strong positive correlation between the structural and functional stability of the vaccine.
"Our new analytical assays for this rPA vaccine have yielded faster and more reliable methodology for monitoring the potency and stability of rPA," Peter Fusco, the vice president of immunobiology and assay development for PharmAthene, said. "In fact, we appear to be making considerable progress towards achieving the 'holy grail' for stability-indicating assays, where the chemistry may ultimately be used to predict the biology. As a result, there are now data that we believe demonstrate the product remains potent and stable for at least two years, and subsequent changes are predicted to proceed at a slow rate."
PharmAthene's rPA anthrax vaccine has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority and the National Institutes of Health.
PharmAthene develops and commercializes next-generation medical countermeasures against chemical and biological threats.